摘要
目的探讨布地奈德联合肺表面活性物质(PS)治疗胎粪吸入综合征(MAS)新生儿的临床效果。方法选择2014年5月~2017年5月中国医科大学航空总医院收治的98例MAS患儿,采用随机数字表法分为对照组和治疗组,每组各49例。对照组给予PS治疗,治疗组给予PS联合布地奈德治疗,均为气管内滴入。评价并比较两组临床疗效。记录并比较两组治疗前(0 h)及治疗后12、24、48 h的动脉血氧分压(PaO_2)、动脉血二氧化碳分压(PaCO_2)及经皮血氧饱和度(TcSaO_2),两组住院时间、氧暴露时间及机械通气时间,两组治疗后并发症的发生情况。结果治疗组的总有效率为93.88%(46/49),高于对照组的75.51%(37/49),差异有统计学意义(P<0.05)。两组治疗后各时间点的PaO_2、PaCO_2、TcSaO_2均明显优于0 h时(P<0.05),且随着时间的延长,PaO_2、TcSaO_2均逐渐升高,PaCO_2均逐渐降低,治疗组在治疗后各时间点的PaO_2、PaCO_2、TcSaO_2均明显优于对照组,差异均有高度统计学意义(P<0.01)。治疗组的住院时间、氧暴露时间及机械通气时间均明显短于对照组,差异有高度统计学意义(P<0.01)。治疗后,治疗组并发症发生率明显低于对照组,差异有统计学意义(P<0.05)。结论布地奈德联合PS治疗MAS的临床效果显著,能够缩短治疗时间,改善患儿的氧合功能,且并发症较少,值得在临床上推广应用。
Objective To study the clinical efficacy of Budesonide combined with pulmonary surfactant（PS） in neonates with meconium aspiration syndrome（MAS）. Methods A total of 98 neonates with MAS in General Hospital of China Aviation of China Medical University from May 2014 to May 2017 were enrolled and divided into the control group（n = 49） and the treatment group（n = 49） by random number table. The control group was treated with PS dropping into trachea, the treatment group was treated with Budesonide combined with PS dropping into trachea, both were intratracheal drops. The clinical efficacy of the two groups; the PaO_2, PaCO_2 and TcSaO_2 of the two groups at the times of before treatment（0 h）, 12 h after treatment, 24 h after treatment and 48 h after treatment; the hospital stays, oxygen exposure time and mechanical ventilation time of the two groups were recorded and compared. The adverse reactions rates of the two groups after treatment were compared. Results The total efficacy rate of the treatment group was93.88%（46/49）, was higher than that of the control group [75.51%（37/49）], the difference was statistically significant（P〈0.05）. The PaO_2, PaCO_2 and TcSaO_2 of the two groups at each time poinits after treatment were significantly better than at the times of 0 h（P〈0.05）, as the extension of time, the PaO_2 and TcSaO_2 gradually increased, the PaCO_2 gradually reduced, and the PaO_2, PaCO_2 and TcSaO_2 of the treatment group at each time points after treatment were significantly better than that of the control group, the differences were statistically significant（P〈0.01）. The hospital stays, oxygen exposure time and mechanical ventilation time of the treatment group were significantly shorter than those of the control group, the differences were statistically significant（P〈0.01）. After treatment, the adverse reaction rate of the treatment group was significantly lower than that of the control group, the difference was statistically significant（P〈0.05）. Conclusion Budesonide combined with PS in the treatment of neonates with MAS has a good efficacy and low adverse reactions, can reduce the treatment time, improve the oxygenation function, it is worth popularizing in clinical application.
作者
王丽
王秋月
WANG Li;WANG Qiuyue(Department of Pediatrics,General Hospital of China Aviation of China Medical University,Beijing 100012,China)
出处
《中国医药导报》
CAS
2018年第23期67-70,共4页
China Medical Herald
基金
首都卫生发展科研专项项目(首发2016-4-9558)
